SK283924B6 - Indazolkarboxamidy - Google Patents

Indazolkarboxamidy Download PDF

Info

Publication number
SK283924B6
SK283924B6 SK1242-97A SK124297A SK283924B6 SK 283924 B6 SK283924 B6 SK 283924B6 SK 124297 A SK124297 A SK 124297A SK 283924 B6 SK283924 B6 SK 283924B6
Authority
SK
Slovakia
Prior art keywords
compound
alkyl
mmol
pharmaceutically acceptable
piperidinyl
Prior art date
Application number
SK1242-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK124297A3 (en
Inventor
John T. Catlow
Marlene L. Cohen
Michael J. Martinelli
John M. Schaus
Steven P. Swanson
Dennis C. Thompson
Thomas M. Wilson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/485,956 external-priority patent/US5654320A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK124297A3 publication Critical patent/SK124297A3/sk
Publication of SK283924B6 publication Critical patent/SK283924B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Luminescent Compositions (AREA)
SK1242-97A 1995-03-16 1996-03-14 Indazolkarboxamidy SK283924B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40511995A 1995-03-16 1995-03-16
US08/485,956 US5654320A (en) 1995-03-16 1995-06-07 Indazolecarboxamides
PCT/US1996/003551 WO1996033713A1 (en) 1995-03-16 1996-03-14 Indazolecarboxamides

Publications (2)

Publication Number Publication Date
SK124297A3 SK124297A3 (en) 1998-02-04
SK283924B6 true SK283924B6 (sk) 2004-05-04

Family

ID=27018928

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1242-97A SK283924B6 (sk) 1995-03-16 1996-03-14 Indazolkarboxamidy

Country Status (23)

Country Link
US (2) US5817676A (xx)
EP (1) EP0732333B1 (xx)
JP (1) JPH11502230A (xx)
CN (1) CN1112923C (xx)
AT (1) ATE203748T1 (xx)
AU (1) AU700842B2 (xx)
BR (1) BR9608223A (xx)
CA (1) CA2215359A1 (xx)
DE (1) DE69614164T2 (xx)
DK (1) DK0732333T3 (xx)
EA (1) EA000699B1 (xx)
ES (1) ES2159345T3 (xx)
GR (1) GR3037029T3 (xx)
HU (1) HU223973B1 (xx)
IL (1) IL117438A (xx)
NO (1) NO312833B1 (xx)
NZ (1) NZ315971A (xx)
PL (1) PL183867B1 (xx)
PT (1) PT732333E (xx)
RO (1) RO119617B1 (xx)
SK (1) SK283924B6 (xx)
TR (1) TR199700956T1 (xx)
WO (1) WO1996033713A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US5914405A (en) * 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
IL141236A0 (en) * 1998-08-21 2002-03-10 Novartis Ag New oral formulations for 5-ht4 agonists or antagonists
DE69935600T2 (de) 1998-09-10 2007-12-06 F. Hoffmann-La Roche Ag Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
WO2002004411A1 (en) 2000-07-07 2002-01-17 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
MXPA03001210A (es) * 2000-08-07 2004-08-12 Smithkline Beecham Corp Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
EP1476151B1 (en) * 2002-02-12 2008-07-16 N.V. Organon 1-arylsulfonyl-3-substitued indole and indoline derivates useful in the treatment of central nervous system disorders
ITMI20030287A1 (it) * 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20031467A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco attivo nel dolore neuropatico
ITMI20031468A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco ativo nel dolore neuropatico
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
WO2009106980A2 (en) * 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145215A (en) * 1961-12-19 1964-08-18 Sterling Drug Inc Indazole derivatives
JP2795460B2 (ja) * 1988-06-20 1998-09-10 協和醗酵工業株式会社 ピラゾロアクリドン誘導体
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
EP0410509A1 (en) * 1989-07-25 1991-01-30 Duphar International Research B.V New substituted 1H-indazole-3-carboxamides
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2116024A1 (en) * 1991-08-20 1993-03-04 Francis David King 5-ht4 receptor antagonists
CA2118798A1 (en) * 1991-09-12 1993-03-18 Francis D. King Azabicyclic compounds as 5-ht4 receptor antagonists
US5763459A (en) * 1992-05-23 1998-06-09 Smithkline Beecham P.L.C. Medicaments for the treatment of anxiety
AU4350493A (en) * 1992-06-27 1994-01-24 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
MX9305947A (es) * 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
TW251287B (xx) * 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
US5817676A (en) 1998-10-06
NZ315971A (en) 1999-01-28
BR9608223A (pt) 1998-12-29
CN1183041A (zh) 1998-05-27
HUP9801386A3 (en) 2000-03-28
JPH11502230A (ja) 1999-02-23
HU223973B1 (hu) 2005-03-29
RO119617B1 (ro) 2005-01-28
NO974221D0 (no) 1997-09-12
GR3037029T3 (en) 2002-01-31
PT732333E (pt) 2001-11-30
ES2159345T3 (es) 2001-10-01
HUP9801386A2 (hu) 1999-06-28
DE69614164T2 (de) 2002-04-25
WO1996033713A1 (en) 1996-10-31
IL117438A (en) 2001-12-23
EA199700242A1 (ru) 1998-04-30
NO312833B1 (no) 2002-07-08
TR199700956T1 (xx) 1998-02-21
AU700842B2 (en) 1999-01-14
CA2215359A1 (en) 1996-10-31
PL322362A1 (en) 1998-01-19
DE69614164D1 (de) 2001-09-06
MX9706967A (es) 1997-11-29
SK124297A3 (en) 1998-02-04
AU6894896A (en) 1996-11-18
US5798367A (en) 1998-08-25
NO974221L (no) 1997-10-27
EP0732333A1 (en) 1996-09-18
DK0732333T3 (da) 2001-10-08
PL183867B1 (pl) 2002-07-31
EP0732333B1 (en) 2001-08-01
IL117438A0 (en) 1996-07-23
EA000699B1 (ru) 2000-02-28
ATE203748T1 (de) 2001-08-15
CN1112923C (zh) 2003-07-02

Similar Documents

Publication Publication Date Title
US5654320A (en) Indazolecarboxamides
US6117882A (en) 5-HT4 agonists and antagonists
JP4931874B2 (ja) リモナバントの結晶多形の製造方法
SK283924B6 (sk) Indazolkarboxamidy
TW202115065A (zh) Kras突變蛋白抑制劑
EP3328853B1 (en) Substituted amide derivatives having multimodal activity against pain
RU2709482C1 (ru) Производные пиперазина, характеризующиеся мультимодальной активностью в отношении боли
AU1345001A (en) 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists
JPWO2002088122A1 (ja) 複素環化合物
JPH0372467A (ja) ピペラジン誘導体
JPH01131145A (ja) 新規アミジノ誘導体
JP2004509106A (ja) ニコチン性アセチルコリン受容体アゴニストとしての（２−アザ−ビシクロ［２．２．１］ヘプト−７−イル）メタノール誘導体
MXPA97006967A (en) Indazolcarboxami
WO2021175848A1 (en) Alpha-methyl-substituted diazabicyclo[4.3.1] decane derivates for treatment of psychiatric disorders
Schaus et al. 5-HT 4 agonists and antagonists
KR20130041381A (ko) ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노－메틸）－페닐아미노］－메틸｝ －１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］－프로피온산 에틸에스테르－메탄설포네이트 및 이를 포함하는 약제학적 조성물
JPH09100276A (ja) （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体及びそれを含有する医薬